Bansal Priya, Margekar Shubha Laxmi, Suman Vivek, Sud Ritika, Meena Shivraj, Sharma Amit K, Islam Sheikh Yasir, Gurtoo Anil, Agrawal Aparna, Pangtey Ghan Shyam, Prakash Anupam
Associate Professor, Lady Hardinge Medical College, New Delhi.
Professor, Lady Hardinge Medical College, New Delhi.
J Assoc Physicians India. 2020 Dec;68(12):58-60.
Coronavirus disease 2019 (COVID 2019) outbreak caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may cause multisystem dysfunction. We studied pancreatic injury (serum amylase and serum lipase levels) in COVID-19 patients.
A retrospective study involving 42 COVID-19 patients (diagnosed by real-time PCR) admitted to a tertiary care hospital was conducted. Serum amylase and serum lipase levels were analysed in relation to severity of COVID-19 and mortality.
Mean age of patients was 50 ± 16 years, with male to female ratio of 3.7:1. Serum amylase was elevated in 14 patients (33%). Serum lipase was elevated in 7 out of 29 patients (24.1%). Mortality was seen in 18 patients (42.8%). Serum amylase or lipase did not correlate with severity of COVID-19 or its mortality. However, both patients who had high lipase (>3times) died.
The prevalence of hyperamylasemia in patients of COVID-19 was 33%, while that of elevated lipase was 24.1%. Pancreatic injury failed to show any statistically significant relation to severity or outcome of COVID-19.
由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的2019冠状病毒病（COVID-19）疫情可能导致多系统功能障碍。我们研究了COVID-19患者的胰腺损伤（血清淀粉酶和血清脂肪酶水平）。
对一家三级医院收治的42例COVID-19患者（通过实时PCR诊断）进行回顾性研究。分析血清淀粉酶和血清脂肪酶水平与COVID-19严重程度及死亡率的关系。
患者的平均年龄为50±16岁，男女比例为3.7:1。14例患者（33%）血清淀粉酶升高。29例患者中有7例（24.1%）血清脂肪酶升高。18例患者（42.8%）死亡。血清淀粉酶或脂肪酶与COVID-19的严重程度或死亡率无关。然而，脂肪酶高（>3倍）的患者均死亡。
COVID-19患者高淀粉酶血症的患病率为33%，脂肪酶升高的患病率为24.1%。胰腺损伤与COVID-19的严重程度或预后未显示出任何统计学上的显著关系。
